Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DABIGATRAN ETEXILATE Cause Gait inability? 23 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 23 reports of Gait inability have been filed in association with DABIGATRAN ETEXILATE (dabigatran etexilate). This represents 0.1% of all adverse event reports for DABIGATRAN ETEXILATE.

23
Reports of Gait inability with DABIGATRAN ETEXILATE
0.1%
of all DABIGATRAN ETEXILATE reports
0
Deaths
13
Hospitalizations

How Dangerous Is Gait inability From DABIGATRAN ETEXILATE?

Of the 23 reports, 13 (56.5%) required hospitalization, and 4 (17.4%) were considered life-threatening.

Is Gait inability Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DABIGATRAN ETEXILATE. However, 23 reports have been filed with the FAERS database.

What Other Side Effects Does DABIGATRAN ETEXILATE Cause?

Gastrointestinal haemorrhage (4,081) Cerebrovascular accident (2,175) Fall (1,786) Ischaemic stroke (1,581) Anaemia (1,412) Haemorrhage (1,324) Death (1,025) Rectal haemorrhage (964) Cerebral haemorrhage (946) Upper gastrointestinal haemorrhage (861)

What Other Drugs Cause Gait inability?

ADALIMUMAB (3,844) ETANERCEPT (2,710) METHOTREXATE (2,559) TOFACITINIB (2,227) SECUKINUMAB (2,216) TOCILIZUMAB (2,139) LEFLUNOMIDE (2,065) RITUXIMAB (2,028) ABATACEPT (2,019) HYDROXYCHLOROQUINE (1,881)

Which DABIGATRAN ETEXILATE Alternatives Have Lower Gait inability Risk?

DABIGATRAN ETEXILATE vs DABRAFENIB DABIGATRAN ETEXILATE vs DABRAFENIB\TRAMETINIB DABIGATRAN ETEXILATE vs DACARBAZINE DABIGATRAN ETEXILATE vs DACLATASVIR DABIGATRAN ETEXILATE vs DACLIZUMAB

Related Pages

DABIGATRAN ETEXILATE Full Profile All Gait inability Reports All Drugs Causing Gait inability DABIGATRAN ETEXILATE Demographics